Form 4: Bristol-Myers Squibb CEO Christopher Boerner Reports Changes in Beneficial Ownership

Christopher Boerner, CEO of Bristol-Myers Squibb, reports transactions involving company stock and derivative securities, including vesting of market share units and distribution of performance shares.

Summary

• Christopher Boerner, the CEO of Bristol-Myers Squibb (BMY), filed a Form 4 detailing changes in his beneficial ownership of the company's securities on March 10, 2025.
• The transactions include the vesting of market share units granted in previous years (2021, 2022, and 2023), resulting in the acquisition of common stock.
• Additionally, performance shares earned under the 2022-2024 Long-Term Performance Award were distributed.
• Shares were also withheld for payment of taxes upon the vesting of awards.
• The reported transactions increased Boerner's direct ownership of BMY common stock.
• The filing also details the nature of market share units and performance shares, including payout factors and vesting conditions.

Sentiment

Score: 7

Explanation: The document primarily reflects routine executive compensation adjustments. The vesting of shares and distribution of performance awards suggest the company is meeting its performance targets, which is a moderately positive signal.

Positives

• The vesting of market share units and distribution of performance shares indicate that the company is meeting certain performance metrics, as these awards are tied to the company's performance.
• The increase in Boerner's direct ownership of BMY common stock could be interpreted as a positive sign, demonstrating his confidence in the company's future.

Negatives

• Shares were withheld for payment of taxes, which reduces the number of shares received by the CEO.

Risks

• The value of market share units and performance shares is dependent on the company's stock price and performance, which are subject to market fluctuations and other risks.
• The vesting of future market share units and performance shares is contingent upon the company meeting certain performance targets, which may not be achieved.

Future Outlook

Future vesting of market share units and distribution of performance shares are subject to the company's performance and certification of results by the Board.

Industry Context

Executive compensation in the pharmaceutical industry often includes stock options, restricted stock, and performance-based equity awards to align management's interests with those of shareholders.

Comparison to Industry Standards

• Companies like Johnson & Johnson (JNJ) and Pfizer (PFE) also utilize equity-based compensation for their executives.
• The specific terms of the market share units and performance shares, such as the payout factors and vesting conditions, are typical for long-term incentive plans in the pharmaceutical industry.
• The vesting schedules and performance metrics are designed to incentivize long-term value creation for shareholders.

Stakeholder Impact

• The vesting of market share units and distribution of performance shares could have a positive impact on shareholder value if the company continues to meet its performance targets.
• The executive compensation structure is designed to align management's interests with those of shareholders, incentivizing long-term value creation.

Next Steps

• Future vesting of market share units and distribution of performance shares in accordance with the terms of the awards.
• Certification of performance results by the Board for future vesting and distribution events.

Key Dates